“It has been a tough time for biotech investors, but a strong biotech rally may be just around the corner,” says leading biotech analyst John McCamant Here, the editor of The Medical Technology Stock Letter looks at a stock that has returned to his recommended buy list – a small cap, anti-cancer treatment firm, Immunogen “Smaller biotechs should receive investor attention when the market turns, as the bulk of...
[read full story]